Open Access

Regulatory role of TRIM21 in the type-I interferon pathway in Japanese encephalitis virus-infected human microglial cells

  • Gunjan Dhawan Manocha1,
  • Ritu Mishra1,
  • Nikhil Sharma1,
  • Kanhaiya Lal Kumawat2,
  • Anirban Basu2 and
  • Sunit K Singh1Email author
Journal of Neuroinflammation201411:24

https://doi.org/10.1186/1742-2094-11-24

Received: 21 November 2013

Accepted: 19 January 2014

Published: 1 February 2014

Abstract

Background

Japanese encephalitis virus (JEV) infection leads to Japanese encephalitis (JE) in humans. JEV is transmitted through mosquitoes and maintained in a zoonotic cycle. This cycle involves pigs as the major reservoir, water birds as carriers and mosquitoes as vectors. JEV invasion into the central nervous system (CNS) may occur via antipodal transport of virions or through the vascular endothelial cells. Microglial cells get activated in response to pathogenic insults. JEV infection induces the innate immune response and triggers the production of type I interferons. The signaling pathway of type I interferon production is regulated by a number of molecules. TRIM proteins are known to regulate the expression of interferons; however, the involvement of TRIM genes and their underlying mechanism during JEV infection are not known.

Methods

Human microglial cells (CHME3) were infected with JEV to understand the role of TRIM21 in JEV infection and its effect on type I interferon (IFN-β) production. Cells were infected in presence and absence of exogenous TRIM21 as well as after knocking down the TRIM21 mRNA. Levels of activated IRF3 expression were measured through Western blot analyses of anti-p-IRF3 antibody, and IFN-β production was measured by using IFN-β real-time PCR and luciferase activity analyses.

Results

JEV infection increased expression of TRIM21 in CHME3 cells. JEV induced an innate immune response by increasing production of IFN-β via IRF3 activation and phosphorylation. Overexpression of TRIM21 resulted in downregulation of p-IRF3 and IFN-β, while silencing led to increased production of p-IRF3 and IFN-β in JEV-infected CHME3 cells.

Conclusion

This report demonstrates TRIM21 as a negative regulator of interferon-β (IFN-β) production mediated by IRF-3 during JEV infection in human microglial cells.

Keywords

Japanese encephalitis virus Viral encephalitis Flavivirus Antiviral mechanism Immune evasion TRIM proteins TRIM21 Type I interferons IRF-3 Vector borne infection

Background

Japanese encephalitis virus (JEV), a flavivirus with single-stranded RNA, is the leading cause of viral encephalitis in most of southeast Asian countries. JEV is transmitted through mosquitoes and maintained in a zoonotic cycle. This cycle involves pigs as the major reservoir/amplifying host, water birds as carriers and mosquitoes as vectors [1]. The estimated worldwide annual incidence of Japanese encephalitis (JE) is about 45,000 human cases and 10,000 deaths [2]. JE leads to long-term neurological damage and significant mortality among children. Approximately 25% of encephalitis patients die, while about 50% of the survivors develop permanent neurologic and/or psychiatric sequelae [1].

The flaviviruses are known to induce proinflammatory response in CNS after infection.

A key step toward induction of innate immunity against viral infections, including JEV, is the production of type I interferons. The presence of virus is sensed by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and RIG-I (retinoic acid-inducible gene 1)-like receptors (RLRs) [3, 4]. The engagement of these (receptors) through pathogen molecular patterns can lead to the production of various cytokines and chemokines and other proinflammatory factors. The key regulators of the induction of type I IFNs during viral infections are RIG-I and MDA5 (melanoma differentiation-associated protein 5) [510]. These are known to interact with MAVS (mitochondrial antiviral signaling protein), which leads to downstream activation of various kinases such as TBK1/IKKε (TANK-binding kinase 1/I kappa B Kinase-ε), which in turn lead to phosphorylation and activation of various transcription factors to induce IFN-β and IFN-α [1113]. The production of type I interferons is crucial for generating antiviral response against viruses. Production of interferons is mediated by various transcription factors such as interferon regulatory factors (IRF). Among the IRF family members, IRF-3 has been well documented to play a role in expression of type I interferons in response to viral infections. Phosphorylation of IRF-3 leads to activation, dimerization and nuclear translocation, ultimately leading to the transcription and production of IFN-β. IFN-β further initiates a cascade of signaling events mediated by IRF-7 and IRF-5 resulting in the production of IFN-γ and activation of various interferon-stimulated genes (ISGs) [8, 14].

The TRIM family (tripartite-motif family) of proteins has been reported for their roles in regulating the innate immune response to viral infections [15]. TRIM proteins are structurally characterized by a RING domain, a B-box domain and a coiled-coil domain [16, 17]. Functionally, most TRIMs are E3 ubiquitin ligases, where RING domains have ubiquitin ligase activity, while the b-Box domains have interacting motifs. TRIM proteins have been reported for their roles in cellular processes such as cell differentiation, transcriptional regulation, signaling cascades and apoptosis [15, 18, 19]. Many TRIM proteins play important roles in antiviral activities [20]. TRIM5 and TRIM22 are known to restrict HIV replication, while TRIM19 has been reported to restrict VSV and herpes simplex virus (HSV) replication [2124]. TRIM21 has been known to play a crucial role in regulating type I interferon production, but its role during viral infections is not well understood [25, 26]. TRIM21 interacts and ubiquitinates IRF-3, IRF-7 and IRF-8 [27]. Due to such interactions, TRIM21 has been implicated in regulating type I interferon signaling directly by modulating the upstream transcription factors. TRIM21 is part of the RoSSA ribonucleoprotein, which includes a single polypeptide and one of four small RNA molecules. TRIM21 has been reported to recognize and degrade viruses in the cytoplasm by binding to antibody-coated virions [28].

This is the first report showing the role of TRIM21 in modulating the type I interferon response upon JEV infection in human microglial cells. We have demonstrated that induction of TRIM21 during JEV infection is a compensatory mechanism to downregulate the type I interferon production mediated by IRF-3. TRIM21 overexpression leads to downregulation of JEV-mediated activation of IRF-3 and downstream IFN-β production, whereas silencing of TRIM21 results in facilitation of JEV-mediated activation of IRF-3 and upregulation of IFN-β production. We thereby report the inhibitory role of TRIM21 on IFN-β production during JEV infection in human microglial cells.

Materials and methods

Materials

The anti-p-IRF3 (Ser396) antibody (#4947S), anti-IRF3 antibody (#4302S), anti-IRF7 (#4920S) and anti-pIRF7 (#5184S) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-β tubulin antibody (#Ab6046) was from Abcam (Cambridge, MA, USA), while anti-TRIM21 antibody (Ro52/SSA) (#sc-25351) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Dulbecco’s Modified Eagle’s Medium (DMEM) (#12100–046) was purchased from Gibco (Rockville, MD, USA). Transfection reagents, Lipofectamine 2000 (#1168-019) and GeneCellin (#GC1000) were from Invitrogen (Carlsbad, CA, USA) and BioCellChallenge, respectively. SiRNA against TRIM21 was purchased from Origene (Rockville, MD, USA) along with Negative control scrambled RNA (TRIM21 Trilencer-27 Human siRNA; #SR304594). IFN-β-luciferase promoter was a kind gift from Dr. Adolfo Garcia-Sastre (Mount Sinai School of Medicine, New York City, NY, USA) while JEV (genotype 1 strain # JaOAr) was gifted by Dr. Anirban Basu (NBRC, Manesar, India). Real-time PCR primers were obtained from Bioserve (Hyderabad, India) and IDT (Belgium, Europe).

Cell culture

Human microglial cell line (CHME3 cells), porcine stable kidney cell line (PS) (for plaque assay) and C6/36 cell line (for viral propagation) were cultured in DMEM (Invitrogen) containing 10% heat-inactivated fetal bovine serum, 100 U penicillin, 100 g/ml streptomycin (#15140122; Invitrogen, Carlsbad, CA, USA) and L-glutamine. All cells were grown in humidified atmosphere containing 5% CO2 and 95% air at 37°C (CHME3 and PS cells) and 28°C (C6/36 cells).

JEV propagation, plaque assay and infection

JEV (genotype 1, JaOAr) was a kind gift from Dr. Anirban Basu, NBRC, India. JEV was further propagated in C6/36 cells. Briefly, C6/36 cells were infected with JEV (MOI 2) in 75 cm2 (T-75) cell culture flasks and incubated for 7 days. Post infection, supernatant was collected and precipitated using a PEG viral precipitation kit (#ab102538; Abcam, Cambridge, MA, USA). Plaque-forming units (PFU) of the propagated virus were determined by plaque assay by using porcine stable kidney cells (PS). Cells were seeded at a density of 1.6 × 105 cells in six-well plates and infected with JEV at different dilutions ranging from 10-3 - 10-10 for 2 h. Post infection, cells were washed with PBS, and 2% low melting agarose overlay [containing 2X-DMEM, 5% FBS and 1% antibiotic (penicillin-streptomycin)] was added to each well. Plates were then incubated at 37°C, 5% CO2, for 96 h. Viral plaques were fixed with 10% HCHO and stained with crystal violet in order to count the number of plaques and determine the PFU for JEV. Further infection experiments in this study were performed using JEV at a multiplicity of infection (MOI) of 5 for 24 h, unless otherwise noted. For infection experiments, CHME3 cells were infected with JEV at an MOI of 5 in incomplete DMEM alone for 3 h. Incomplete media were replaced by complete growth media (DMEM with 10% FBS and antibiotics) 3 h later. Cells were harvested at 24 h post infection for RNA and/or protein isolation.

TRIM21 overexpression and knockdown

TRIM21 was cloned into the pcDNA3.1 vector. The product was sequenced for confirmation and transformed into DH5α competent cells. The plasmid was then isolated using Qiagen maxi-prep kit (#12163; Qiagen, Hilden, Germany) and observed on a 0.8% agarose gel for purity. A truncated form of TRIM21 without the N-terminal RING domain was also cloned into the pcDNA3.1 vector, to be known as TRIM21 (ΔRING) in this study. TRIM21 protein is comprised of a RING domain from the 16th - 54th amino acid. Therefore, the TRIM21 (ΔRING) primers were designed in such a way that the reverse primer was similar to the wild-type TRIM21 clone, while the forward primer was designed such as to start the polymerase reaction from the 163rd nucleotide so that the RING domain from the wild-type TRIM21 sequence was completely removed. The PCR product was checked on an agarose gel (Figure 1A). The PCR product was further eluted out of agarose gel and digested using EcoR1 and HINDIII enzymes. Along with this insert, the pcDNA3.1 vector was also digested using the same enzymes. Following digestion, the vector and insert were ligated using T4 ligase at 15°C overnight. The ligated product was transformed into E. coli DH5α competent cells and spread on an LA agar plate with ampicillin and incubated at 37°C for 15–16 h. The resultant colonies were checked with PCR using TRIM21 (ΔRING) primers, and the positive colonies were further inoculated in LB media to isolate the plasmid using the Qiagen miniprep kit (#27104, Qiagen, Hilden, Germany) according to manufacturer’s protocol. The resultant plasmid was validated by sequencing and used for transfection studies. To validate the expression of truncated TRIM21, CHME3 cells were transfected with TRIM21 (WT) and TRIM21 (ΔRING) for 48 h. Lysates were resolved on SDS-PAGE and probed with for anti-TRIM21 antibody by Western blot. For overexpression, 1 day prior to transfection, CHME3 cells were seeded in 25 cm2 cell culture flasks at 70% confluency. Cells were transfected with 4 μg of either TRIM21 or TRIM21 (ΔRING) plasmid per 600,000 cells using GeneCellin transfection reagent in 4 ml transfection media (DMEM with 10% FBS). Cells were replenished with complete growth media (DMEM + 10% FBS + antibiotics) after 8 h of transfection and incubated for 48 h. In cases of infection experiments, 24 h post transfection, cells were infected with JEV at MOI 5 and lysed 24 h post infection. In case of silencing of TRIM21, siRNA against TRIM21 was transfected to CHME3 cells in six-well plates (1.5 × 105 cells per well) using Lipofectamine 2000 transfection reagent. Cells were either non-transfected (control), transfected with scrambled RNA provided in the siRNA kit (negative control) or transfected with siRNA duplex for 48 h. Cells were infected 24 h post transfection in the experiments wherever required.
Figure 1

TRIM21 attenuates the JEV mediated upregulation of the p-IRF3 level and IFN-β level in human microglial cells. (A) PCR amplification of TRIM21 and TRIM21 (ΔRING) primers was carried out and the product run on 1% agarose gel (upper panel). Expression of wild-type TRIM21 as well as the TRIM21 (ΔRING) domain was confirmed by Western blotting (lower panel). (B) CHME3 cells were transfected with 4 μg of TRIM21 plasmid or TRIM21 (ΔRING) for 48 h. Cell lysates were resolved on SDS-PAGE and probed with anti-TRIM21, anti-IRF-3 and anti-β-tubulin antibodies by Western blotting. Representative image is shown. (C) Cells transfected with TRIM21 or TRIM21 (ΔRING) were infected with JEV, and total RNA was isolated post 48 h of transfection. Real-time PCR for IFN-β1 was performed, and an average of three independent sets of experiments is plotted and shown. (D) Luciferase assay for IFN-β for cells transfected with TRIM21 or TRIM21 (ΔRING) and infected with JEV along with respective controls was performed. Luciferase activity normalized against β-gal activity was averaged and plotted (*p <0.05, **p < 0.01, ***p < 0.001 from control).

Western blotting

Cells were transfected with TRIM21 plasmid for overexpression studies and siRNA for silencing studies as described above. After 48 h of transfection, cells were lysed using RIPA (150 mM NaCl, 50 mM Tris–HCl, pH 7.5, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) buffer containing 1 μM PMSF and 1X protease inhibitor cocktail, ProteCEASE-50 (#427P; G-Biosciences, St. Louis, MO, USA). Protein was quantified using Bradford assay [29]. Lysates were resolved on SDS-PAGE and Western blotted using the desired antibodies against p-IRF3 (1:3,000 dilution), IRF3 (1:3,000), TRIM21 (1:5,000), p-IRF7 (1:3,000) and IRF7 (1:3,000). Optical densities for p-IRF3, p-IRF7 and TRIM21 from visualized Western blots were normalized to their respective loading controls (IRF3/IRF7/β-tubulin) and averaged from three independent experiments.

Real-time PCR

For RNA isolation, cells were harvested and total RNA isolated using Qiagen RNeasy kit (#74106; Qiagen, Hilden, Germany). Synthesis of cDNA was performed using Superscript II reverse transcriptase system (#11904-018; Invitrogen, Carlsbad, CA, USA) according to manufacturer’s protocol using 2,000 ng RNA. Thermal cycles of cDNA synthesis using random hexamers were as follows: 65°C (5 min); 25°C (10 min); 42°C (50 min); 70°C (10 min); followed by treatment with RNase H for 20 min at 37°C. For amplification, 100 ng cDNA was used as a template for performing RT-PCR using SYBR Green Supermix (#4367659; Applied Biosystems, Warrington, UK). Sequences of all the primers used for various genes in this study are mentioned in Table 1.
Table 1

List of primers

Gene name

Primer sequence (5′-3′)

TRIM21

Fwd: 5′ AGAGAGACTTCACCTGTTCTGT 3′

Rev: 5′ TCAGTTCCCCTAATGCCACCT 3′

TRIM21 (ΔRING)

Fwd: 5′ TACGAATTCCGGCAGCGCTTTCTGCTC 3′

Rev: 5′ GCCAAGCTTATAGTCAGTGGATCCTTG 3′

IFN-β1

Fwd: 5′ GCTCTCCTGTTGTGCTTCTCCAC 3′

Rev: 5′ CAATAGTCTCATTCCAGCCAGTGC 3′

β-Actin

Fwd: 5′ GTCTGCCTTGGTAGTGGATAATG 3′

Rev: 5′ TCGAGGACGCCCTATCATGG 3′

IFN-β luciferase assay

CHME3 cells were seeded at a density of 65,000 cells per well in 12-well Plates 1 day prior to transfection. Cells were transfected with IFN-β-Luc reporter plasmid (1 μg/ml) and β-gal (350 ng/ml) in 1 ml of transfection media (DMEM + 10% FBS). In case of TRIM21 overexpression, 1 μg/ml TRIM21 plasmid was co-transfected, while in case of knockdown, 10nM siRNA for TRIM21 was co-transfected. In conditions where infection was required, cells were infected with JEV (MOI 5) 24 h post transfection. After 48 h of transfection (24 h after infection), cells were harvested and luciferase assay performed using the Luciferase assay kit (#E4030; Promega, Madison, WI, USA) according to the manufacturer’s protocol. Cells were lysed in 150 μl 1X lysis buffer and centrifuged at 12,000 g for 3 min, and the supernatant was used for luminescence measurement using the Luciferase assay reagent. Normalization was done by performing a β-galactosidase assay using the β-galactosidase kit (#E2000; Promega, Madison, WI, USA). For this assay, 50 μl of the lysate supernatant was incubated with 50 μl 2X assay buffer at 37°C for 30 min, and the resulting yellow color was read at 420 nm. β-gal activity (in milliunits) in each of the lysates was obtained using a standard curve, and IFN-β luciferase activity was normalized (against β-gal activity), averaged and plotted for three independent sets of experiments.

Statistical analysis

Data are presented as mean ± standard error. Statistical significance was calculated by using one-way ANOVA and/or Student’s t-test. The Tukey-Kramer multiple comparisons post hoc test was used to determine P-values.

Results

JEV induces IFN-β production in a time-dependent manner in human microglial cells

In order to verify the innate immune response being generated during JEV infection, we studied the level of IFN-β mRNA as well as IFN-β luciferase activity in microglial cells. Human microglial cells (CHME3) were infected with JEV at an MOI of 5 and harvested at various time intervals of 6, 12, 24 and 36 h. Infected cells were lysed using the reporter lysis buffer for the IFN-β-luciferase assay. IFN-β luciferase activity increased with JEV infection in a time-dependent manner until 24 h (Figure 2A). Since the maximal increase in IFN-β levels was observed at 24 h, all further experiments were performed at the 24-h time point. CHME3 cells were infected with JEV (MOI 5) for 24 h and harvested for RNA isolation. As seen in Figure 2B, IFN-β mRNA levels were significantly increased with JEV infection over the control (Figure 2B). These data confirm the activation of an immune response in terms of IFN-β production following JEV infection in CHME3 cells.
Figure 2

JEV infection leads to a time-dependent increase in IFN-β luciferase activity in human microglial cells. (A) CHME3 cells were transfected with IFN-β-luciferase promoter plasmid and β-gal promoter plasmid and infected with JEV at MOI 5 for 6, 12, 24 and 36 h. Luciferase activity was measured, normalized and averaged for three independent experiments. (B) CHME3 cells were infected with JEV at MOI 5 for 24 h and total RNA isolated and quantified by real-time PCR for IFN-β1 levels. Fold change of the IFN-β1 mRNA level for three independent experiments was averaged and plotted (*p < 0.05, **p < 0.01, ***p < 0.001 from control, # p from 6 h, $ p from 12 h).

JEV induces phosphorylation of interferon regulatory factor-3

In most of the viral infections, the production of type I interferon is a key host immune response. This is mediated by various interferon regulatory factors such as IRF-3 (interferon regulatory factor-3) and IRF-7 (interferon regulatory factor-7). JEV-infected CHME3 cells showed significantly higher levels of active, phosphorylated IRF-3 as compared to controls (Figure 3A). An increase in p-IRF3 levels as seen by Western blotting corresponds with the production of IFN-β (Figure 2), observed at 24 h of JEV infection. Alternatively, IRF-7 phosphorylation was not affected in CHME3 cells infected with JEV at MOI 5 for 24 h (Figure 3B).
Figure 3

JEV induces phosphorylated IRF-3 levels in human microglial cells. (A) CHME3 cells were either un-infected or infected with JEV at MOI 5 for 24 h. Cell lysates were resolved on SDS-PAGE and probed with anti-p-IRF3 antibody, anti-p-IRF7, anti-IRF3 and anti-IRF7 antibodies, and anti-β-tubulin antibody (loading control) by Western blotting. Representatives of three independent experiments are shown. (B) Densitometry analyses of Western blot experiments were performed with normalizing p-IRF-3 and p-IRF-7 against their respective controls IRF-3 and IRF-7 as well as against β-tubulin (***p <0.001, *p < 0.05 from control).

JEV infection induces the expression of TRIM21 in human microglial cells in a time-dependent manner

TRIM21, an autoantigen, is known to interact with IRF-3, IRF-7 and IRF-8. Because of these interactions, it is a key regulator of the type I interferon immune response. TRIM21 is an E3 ubiquitin ligase that can interact with and ubiquitinate its target molecules. Since JEV induces p-IRF3 and IFN-β expression in human microglial cells (CHME3), we tried to understand the role of TRIM proteins, specifically TRIM21, in regulation of the type I interferon pathway. In order to identify the involvement of TRIM21 in JEV-infected CHME3 cells, we first determined the effect of JEV on the TRIM21 level in the cells. CHME3 cells were infected with JEV (MOI 5) and harvested at various time points. TRIM21 codes for 52 KDa RoSSA protein and Western blotting against the antibody for this protein (from hereon called TRIM21 protein) showed a time-dependent increase in TRIM21 levels for up to 36 h (Figure 4A). CHME3 cells infected with JEV at MOI 5 for 24 h showed increased mRNA levels for the TRIM21 gene (Figure 4B). Additionally, a time-course experiment for JEV infection was performed in HeLa cells to observe the expression of IFN-β as well as TRIM21. Although IFN-β levels increased upon JEV infection after 12 h, there was no change in TRIM21 levels in HeLa cells following JEV infection at any given time point (Additional file 1: Figure S1A & B). This suggested that the role of TRIM21 during JEV infection is specific to human microglial cells.
Figure 4

JEV induces TRIM21 protein levels in human microglial cells in a time-dependent manner. (A) CHME3 cells were either un-infected or infected with JEV at MOI 5 for 6, 12, 24 and 36 h. Cell lysates were resolved on SDS-PAGE and probed with anti-TRIM21 antibody and anti-β-tubulin antibody (loading control) by Western blotting. A representation of three independent experiments is shown along with densitometry analysis with normalization of TRIM21 against β-tubulin, averaging and plotting. (B) CHME3 cells were infected with JEV for 24 h (MOI 5). Total RNA was isolated from harvested cells. cDNA prepared by reverse transcription of control and infected samples was used as a template for qPCR against primers for TRIM21 gene. Average fold change in the TRIM21 mRNA level from three independent experiments is plotted and shown (*p < 0.05, **p < 0.01, ***p < 0.001 from control, # p from 6 h, $p from 12 h).

TRIM21 overexpression attenuates JEV-mediated upregulation of p-IRF3

Since TRIM21 interacts with IRF-3 directly, it has an important regulatory role in the immune response. We hypothesized that the upregulation of TRIM21 in JEV-infected cells could be a mechanism toward counteracting the production of type I interferons and/or an antiviral response towards the virus infection. The exogenous TRIM21 may further enhance this counteraction and may attenuate the effects in JEV-infected CHME3 cells in terms of IRF3 phosphorylation. Therefore, TRIM21 was overexpressed in CHME3 cells via plasmid transfection in order to observe the effect of TRIM21 on the IRF-3 level and JEV-mediated IRF-3 phosphorylation. The presence of exogenous TRIM21 and TRIM 21 (ΔRING) in CHME3 cells was observed through Western blotting studies. As shown in Figure 1A, TRIM21-transfected CHME3 cells showed TRIM21 antibody reactivity by Western blotting at 52 KDa, while cells transfected with TRIM 21 (ΔRING) showed a band slightly lower than the 52 KDa mark. Cells transfected with TRIM21 were infected by JEV after 24 h of transfection, and lysates were probed for phosphorylated IRF3 levels by Western blotting. As expected, JEV infection increased p-IRF3 levels in CHME3 cells as compared to control (GFP vector-transfected controls). However, overexpression of TRIM21 prior to infection resulted in a reduction of p-IRF3 levels post infection compared to the CHME3 cells only infected with JEV without TRIM21 transfection (Figure 1B). This suggests that TRIM21 could result in attenuation of JEV-mediated IRF-3 activation. Therefore, TRIM21 had an inhibitory effect on IRF3 activation. The total IRF-3 level was unaltered in the CHME3 cells infected with JEV, but TRIM21 overexpression reduced the level of total IRF3. This suggests that TRIM21 directly inhibits unphosphorylated IRF-3 in the presence or absence of JEV infection. This was further validated by using TRIM21 (ΔRING) plasmid in transfection studies. TRIM21 lacking the RING domain had no effect on the IRF3 level (Figure 1A,B). As a result, p-IRF3 levels were also not attenuated in TRIM21 (ΔRING)-transfected CHME3 cells following JEV infection (Figure 1B).

TRIM21 overexpression represses JEV-mediated elevation in IFN-β levels

We observed an increased production of IFN-β in JEV-infected CHME3 cells (Figure 2). Since TRIM21 transfection attenuates the activation of IRF3, it can be expected that TRIM21 leads to downstream inhibitory effects as well. Hence, in order to understand the role of TRIM21 on IFN-β production, we checked the levels of IFN-β mRNA as well as IFN-β luciferase activity in TRIM21-overexpressed CHME3 cells. Human IFN-β is encoded by the IFN-β1 gene. CHME3 cells were transfected with TRIM21 plasmid and infected with JEV 24 h post transfection. The CHME3 cells were harvested and RNA isolated for real-time quantification of the IFN-β1 mRNA level using the primers mentioned in Table 1, and fold change in the mRNA level was determined by normalizing the IFN-β1 Ct values against those of β-actin. As observed in Figure 2B, we found an increased expression of IFN-β1 at mRNA levels in JEV-infected CHME3 cells as compared to vector controls (Figure 1C). However, we observed the reduction in IFN-β1 levels in JEV-infected TRIM21-transfected CHME3 cells in accordance with IRF-3 activation compared to controls. CHME3 cells transfected with truncated TRIM21 lacking the RING domain showed no reduction in IFN-β1 mRNA levels. A similar trend was observed with IFN-β luciferase activity. Cells were transfected with IFN-β-luciferase promoter and β-gal with or without TRIM21 plasmid followed by JEV infection. Luciferase activity was measured 48 h post transfection. JEV-infected cells showed significantly higher luciferase activity of IFN-β-luciferase promoter; however, transfection of TRIM21 before JEV infection attenuated JEV-mediated luciferase activity (Figure 1D). This observation suggests that TRIM21 has an inhibitory role in interferon-β production after JEV infection.

TRIM21 silencing facilitates JEV-mediated upregulation of the p-IRF3 level in CHME3 cells

To further confirm the inhibitory role of TRIM21 on IFN-β production, siRNA against TRIM21 was used to knock down the expression of TRIM21 in CHME3 cells. Silencing of TRIM21 was performed by using commercially available siRNA duplexes against TRIM21 that resulted in >70% knockdown of TRIM21 as shown in Figure 5A. Since JEV infection stimulated IRF3 activation and phosphorylation, this phenomenon was checked following TRIM21 silencing. JEV-infected CHME3 cells showed increased phosphorylation of IRF3 as compared to controls; however, silencing of TRIM21 prior to infection further enhanced the phosphorylation and activation of IRF3 (Figure 5B). This further confirmed the inhibitory role of dysregulated endogenous TRIM21 during JEV infection in human microglial cells.
Figure 5

TRIM21 knockdown facilitates JEV-mediated IRF3 activation and upregulation of the IFN-β level. (A) Cells were either transfected with negative control RNA (NC) or transfected with 10nM siRNA against TRIM21 for 48 h. Cell lysates were resolved on SDS-PAGE and probed with anti-TRIM21 antibody and anti-β-tubulin antibody by Western blotting. A representative image is shown. (B) Cells were either non-transfected (C), transfected with negative control RNA (NC) or with TRIM21 siRNA for 24 h followed by JEV infection for 24 h. Cell lysates were resolved on SDS-PAGE and probed with anti-p-IRF3 antibody, anti-IRF3 and anti-β-tubulin antibodies (loading control) by Western blotting. A representative of three independent experiments is shown. Densitometry analyses of Western blot experiments were performed with normalizing p-IRF-3 and p-IRF-3 against β-tubulin. (C) Real-time PCR for IFN-β1 for siRNA-transfected and JEV-infected cells along with the respective controls was performed and averaged for three independent sets of experiments. (D) Luciferase assay for IFN-β for cells transfected with siRNA against TRIM21 and infected with JEV along with respective controls was performed. Luciferase activity normalized against β-gal activity was averaged and plotted (**p < 0.01, ***p < 0.001 from control).

TRIM21 silencing upregulates the JEV-mediated increase in IFN-β level

Further downstream from IRF3 activation, the expression level of IFN-β was checked in order to confirm the role of TRIM21 in modulating the expression of the interferon in case of JEV infection. Again, corresponding to the IRF3 activation, JEV-infection resulted in an additional increase in the IFN-β mRNA level as well as IFN-β-luciferase activity in CHME3 cells, where TRIM21 was silenced prior to the JEV infection (Figure 5C,D).

Discussion

This study reports that JEV infection induces the expression of TRIM21 in human microglial cells. Exogenous overexpression of TRIM21 attenuates JEV-mediated activation and phosphorylation of IRF3 as well as expression of IFN-β levels. In addition, TRIM21 silencing leads to facilitation of JEV-mediated IRF3 phosphorylation and downstream induction of IFN-β.

We demonstrated that JEV induces IRF3 activation at 24 h of JEV infection. However, levels of phosphorylated IRF7 are not significantly different in the infected cells as compared to control after 24 h. IRF7 has been reported to become activated only during the early phases of JEV infection, and the levels of p-IRF7 are not elevated during late phases of JEV infection [30]. Therefore, our study was focused on understanding the role of TRIM protein during JEV infection in the type I interferon pathway in terms of IRF3 activation as well as its effect on the expression of IFN-β. The production of IFN-β by JEV is known to occur through the RIG-1-mediated pathway [3]. However, the role of TRIM proteins in modulating the immune response in JEV infection had not yet been reported.

TRIM proteins are known to act as antiviral molecules because of their specific actions against specific viruses, as well as regulators of immune signaling pathway [15, 25, 31, 32]. TRIM79α is reported to restrict viral replication of the tick-borne encephalitis virus (TBEV), but not other flaviviruses, such as West Nile virus [33]. TRIM56 has been reported to restrict bovine viral diarrhea virus replication in vitro [34]. The antiviral activity of TRIM21 has been reported to be through the antibody-mediated pathway [28, 35]. It targets the virus toward proteasomal degradation by ubiquitination. Vaysburd et al. [28] showed that sensing of antibody-coated pathogens through TRIM21 increased in the case of nonenveloped DNA viruses, RNA viruses and intracellular bacterial infections [28, 35]. While TRIM21 acts as an Fc receptor in sensing the antibody-coated viruses, the modulation of the immune signaling pathway by TRIM21 is dependent on the targeting of interferon regulatory factors via ubiquitination. We observed that JEV increases the expression of TRIM21 in CHME3 cells as a negative regulator of the type I interferon-mediated pathway. Two schools of thoughts exist regarding the action of TRIM21 in modulating the interferon pathway [2527, 3638]. One suggests that TRIM21 promotes degradation of IRF-3 and IRF-7, thereby limiting type I interferon production. Our study supports the same findings as we observed the degradation of IRF-3 by TRIM21 in CHME3 cells; hence, the availability of less phosphorylated forms of IRF-3 ultimately leads to reduced expression of IFN-β [26, 37]. Since there was no change in IRF3 levels and subsequent IFN-β levels upon TRIM21 (ΔRING) transfection, it suggested that the E3 ligase activity of TRIM21 may be responsible for the regulation of IRF3 expression. Our finding supports the those of Higgs et al. [26] in which they showed that both the RING domain and the SPRY domain are equally required to regulate the expression of IRF3 by the interaction and proteasomal degradation of IRF3 [26]. Hence, the absence of any one of the domains is sufficient to validate the role of TRIM21 in IRF3 and IFN-β regulation during JEV infection. The other school of thought supports the stabilization of IRF3 expression through a TRIM21-mediated pathway. This has been reported in the case of Sendai virus infection, where TRIM21 acts as a positive regulator of the IRF3 pathway during viral infection [27]. This functional variability could be attributed to being dependent on the type of viral infection, the duration of infection and the upstream signaling pathway. Apart from RNA virus recognition, TRIM21 is also able to modulate DNA virus infections. TRIM21 has been shown to interact with DDX41, a cytosolic DNA sensor that triggers type I IFN responses [39]. TRIM21 causes ubiquitination of DDX41, leading to a lesser production of IFN-β. A number of other TRIM proteins are also involved in modulating the inflammatory signaling pathways. TRIM30 (TRIM79α) is reported to be involved in lysosomal degradation of TAK1 binding protein 2 (TAB2) and TAK1 binding protein 3 (TAB3) downstream of the TLR4 pathway, leading to the inhibition of NF-ҡB induction during LPS stimulation [40]. Like TRIM21, TRIM27 is also known to target IKKs, thereby negatively regulating PRR pathways [41]. TRIM5α is also known to negatively regulate NF-ҡB and mitogen-activated protein kinase (MAPK) signaling pathways by targeting TGF-β-activated kinase 1 (TAK1), and these activities are known to be uncoupled from the retroviral capsid recognition [42, 43]. TAK1 has also been reported to be targeted by TRIM8 [44]. TRIM5α has also been reported to positively regulate NF-ҡB signaling, AP-1 activation and expression of proinflammatory cytokines [42]. TRIM23 acts as a cofactor in the regulation of NF-ҡB activation in human cytomegalovirus infection [45]. Therefore, the modulation of immune responses by TRIM proteins can be highly specific based on the type of pathogens and their derivatives.

The increased expression of TRIM21 during JEV infection and its inhibitory role act as a feedback mechanism to attenuate the immune response (Figure 6). This is supported by the observation that the activation of IRF3 in JEV infection is further enhanced by knockdown of TRIM21 in CHME3 cells prior to infection. Consequently, the IFN-β level was also increased in JEV-infected TRIM21 knocked-down cells. The expression of TRIM21 has also been reported to be induced by IFN-α and IFN-β via the IRF-mediated pathway [46]. Other TRIM proteins, such as TRIM5α and TRIM19, can also be altered by type I IFNs [4751]. Two independent studies have reported the expression of many TRIM proteins following type I interferon stimulation in mouse macrophages, dendritic cells, primary human-monocyte-derived macrophages and human primary lymphocytes [47, 48]. Zhao et al. [52] reported that TRIM 38 acts as a negative feedback regulator of NF-ҡB signaling in TLR agonist-treated macrophages [52]. This evidence along with our observations suggests the involvement of a possible feedback mechanism for the expression of TRIM proteins by interferon-mediated responses during viral infections. In summary, we suggest that JEV infection in human microglial cells triggers an innate immune response in terms of IFN-β production. The expression of IFN-β in turn is suppressed by increased expression of TRIM21 during JEV infection in human microglial cells. Probably JEV utilizes this strategy to suppress the type I interferon response as a part of an immune evasion mechanism. However, further studies are required to understand the involvement of other TRIM proteins as an antiviral factor against other flaviviruses in order to understand the mechanisms of pathogenesis as well as to develop therapeutic tools.
Figure 6

Model showing a plausible role of TRIM21 as a negative regulator of IRF3 activation and IFN-β production following JEV infection in human microglial cells. JEV infection causes activation of the RIG-1 receptor, initiating a downstream signaling mechanism leading to the activation of IRF-3. Phosphorylated IRF-3 dimerizes and translocates into the nucleus, where it leads to the transcription and production of IFN-β. JEV infection also induces the TRIM21 protein, which negatively regulates IRF-3 phosphorylation, leading to reduced IFN-β production. The upregulation of TRIM21 is proposed to be a feedback mechanism to inhibit the innate immune response in JEV infection.

Conclusion

JEV infection in human microglial cells induced the expression of TRIM21 protein. Exogenous expression of TRIM21 in human microglial cells resulted in attenuation of JEV-mediated effects in terms of activation of interferon regulatory factor-3 and production of interferon-β. Further knockdown of TRIM21 enhances the JEV-mediated IRF-3 activation and IFN-β production. Although upstream mechanisms of JEV-mediated IRF-3 phosphorylation are known, this study provides the first evidence of the involvement of TRIM21 protein in negatively regulating the innate immune response by targeting IRF-3-mediated IFN-β production during JEV infection. JEV could exploit this strategy to suppress the type I interferon response during the early course of infection.

Abbreviations

JEV: 

Japanese encephalitis virus

JE: 

Japanese encephalitis

PRR: 

Pattern recognition receptors

RLR: 

RIG-1 like receptors

RIG-1: 

Retinoic acid-inducible gene 1

MDA5: 

Melanoma differentiation-associated protein 5

MAVS: 

Mitochondrial antiviral signaling protein

TLR: 

Toll-like receptors

TBK: 

Tank binding kinase

TGF: 

Transforming growth factor

IFN: 

Interferon

IRF: 

Interferon regulatory factor

TRIM: 

Tripartite motif

ISG: 

Interferon-stimulated genes

TAB2: 

TAK1 binding protein 2

TAB3: 

TAK1 binding protein 3

LPS: 

Lipopolysaccharide

MAPK: 

Mitogen-activated protein kinase

HSV: 

Herpes simplex virus.

Declarations

Acknowledgements

The authors are thankful to Prof. Adolfo Garcia-Sastre, Department of Medicine and Microbiology, Mount Sinai School of Medicine, NY, New York, USA, forproviding the IFN-β-luciferase promoter as a kind gift. We are also thankful to Dr. Rajesh Singh, Associate Professor, Department of Biotechnology, MS University, Baroda, for useful discussions and support. The authors are also thankful to the director, Centre for Cellular and Molecular Biology (CCMB), Hyderabad, for his support. The financial support to GDM toward her postdoctoral fellowship through the CSIR network project (miND-BSC0115) is highly acknowledged. The authors acknowledge the financial support through the Indo-Korean Grant (INT/Korea/P-08) funded by the Department of Science and Technology, Government of India, New Delhi.

Authors’ Affiliations

(1)
Laboratory of Neurovirology and Inflammation Biology, CSIR-Centre for Cellular and Molecular Biology (CCMB)
(2)
National Brain Research Center (NBRC)

References

  1. Unni SK, Ruzek D, Chhatbar C, Mishra R, Johri MK, Singh SK: Japanese encephalitis virus: from genome to infectome. Microbes Infect. 2011, 13: 312-321.View ArticlePubMedGoogle Scholar
  2. van den Hurk AF, Ritchie SA, Mackenzie JS: Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol. 2009, 54: 17-35.View ArticlePubMedGoogle Scholar
  3. Nazmi A, Dutta K, Basu A: RIG-I mediates innate immune response in mouse neurons following Japanese encephalitis virus infection. PLoS One. 2011, 6: e21761.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Lee MS, Kim YJ: Pattern-recognition receptor signaling initiated from extracellular, membrane, and cytoplasmic space. Mol Cells. 2007, 23: 1-10.PubMedGoogle Scholar
  5. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, et al: Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006, 441: 101-105.View ArticlePubMedGoogle Scholar
  6. Yoneyama M, Fujita T: Structural mechanism of RNA recognition by the RIG-I-like receptors. Immunity. 2008, 29: 178-181.View ArticlePubMedGoogle Scholar
  7. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, Diamond MS, Colonna M: Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA. 2006, 103: 8459-8464.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, et al: Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol. 2004, 5: 1061-1068.View ArticlePubMedGoogle Scholar
  9. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell. 2006, 124: 783-801.View ArticlePubMedGoogle Scholar
  10. Peterson KE, Du M: Innate immunity in the pathogenesis of polytropic retrovirus infection in the central nervous system. Immunol Res. 2009, 43: 149-159.View ArticlePubMedGoogle Scholar
  11. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T: IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003, 4: 491-496.View ArticlePubMedGoogle Scholar
  12. Sharma S, Benjamin R, Grandvaux N, Zhou GP, Lin R, Hiscott J: Triggering the interferon antiviral response through an IKK-related pathway. Science. 2003, 300: 1148-1151.View ArticlePubMedGoogle Scholar
  13. McWhirter SM, Fitzgerald KA, Rosains J, Rowe DC, Golenbock DT, Maniatis T: IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci USA. 2004, 101: 233-238.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T: Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. Embo J. 1998, 17: 1087-1095.PubMed CentralView ArticlePubMedGoogle Scholar
  15. McNab FW, Rajsbaum R, Stoye JP, O'Garra A: Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol. 2011, 23: 46-56.View ArticlePubMedGoogle Scholar
  16. Han K, Lou DI, Sawyer SL: Identification of a genomic reservoir for new TRIM genes in primate genomes. PLoS Genet. 2011, 7: e1002388.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Short KM, Cox TC: Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding. J Biol Chem. 2006, 281: 8970-8980.View ArticlePubMedGoogle Scholar
  18. Schwamborn JC, Berezikov E, Knoblich JA: The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell. 2009, 136: 913-925.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Sato T, Okumura F, Kano S, Kondo T, Ariga T, Hatakeyama S: TRIM32 promotes neural differentiation through retinoic acid receptor-mediated transcription. J Cell Sci. 2011, 124: 3492-3502.View ArticlePubMedGoogle Scholar
  20. Uchil PD, Hinz A, Siegel S, Coenen-Stass A, Pertel T, Luban J, Mothes W: TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol. 2011, 87: 257-272.View ArticleGoogle Scholar
  21. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004, 427: 848-853.View ArticlePubMedGoogle Scholar
  22. Yap MW, Nisole S, Lynch C, Stoye JP: Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA. 2004, 101: 10786-10791.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Geoffroy MC, Chelbi-Alix MK: Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res. 2011, 31: 145-158.View ArticlePubMedGoogle Scholar
  24. Hattlmann CJ, Kelly JN, Barr SD: TRIM22: a diverse and dynamic antiviral protein. Mol Biol Int. 2012, 2012: 153415.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Jefferies C, Wynne C, Higgs R: Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease?. Nat Rev Immunol. 2011, 11: 617-625.View ArticlePubMedGoogle Scholar
  26. Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA: The E3 ubiquitin ligase Ro52 negzatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3.J Immunol. 2008, 181: 1780-1786.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Yang K, Shi HX, Liu XY, Shan YF, Wei B, Chen S, Wang C: TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol. 2009, 182: 3782-3792.View ArticlePubMedGoogle Scholar
  28. Vaysburd M, Watkinson RE, Cooper H, Reed M, O'Connell K, Smith J, Cruickshanks J, James LC: Intracellular antibody receptor TRIM21 prevents fatal viral infection.Proc Natl Acad Sci USA. 2013, 110: 12397-12401.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254.View ArticlePubMedGoogle Scholar
  30. Nazmi A, Mukhopadhyay R, Dutta K, Basu A: STING mediates neuronal innate immune response following Japanese encephalitis virus infection. Sci Rep. 2012, 2: 347.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Ozato K, Shin DM, Chang TH, Morse HC: TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008, 8: 849-860.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Versteeg GA, Rajsbaum R, Sanchez-Aparicio MT, Maestre AM, Valdiviezo J, Shi M, Inn KS, Fernandez-Sesma A, Jung J, Garcia-Sastre A: The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity. 2013, 38: 384-398.PubMed CentralView ArticlePubMedGoogle Scholar
  33. Taylor RT, Lubick KJ, Robertson SJ, Broughton JP, Bloom ME, Bresnahan WA, Best SM: TRIM79alpha, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase. Cell Host Microbe. 2011, 10: 185-196.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Wang J, Liu B, Wang N, Lee YM, Liu C, Li K: TRIM56 is a virus- and interferon-inducible E3 ubiquitin ligase that restricts pestivirus infection. J Virol. 2011, 85: 3733-3745.PubMed CentralView ArticlePubMedGoogle Scholar
  35. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC: Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013, 14: 327-336.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Young JA, Sermwittayawong D, Kim HJ, Nandu S, An N, Erdjument-Bromage H, Tempst P, Coscoy L, Winoto A: Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production. J Biol Chem. 2011, 286: 6521-6531.PubMed CentralView ArticlePubMedGoogle Scholar
  37. Higgs R, Lazzari E, Wynne C, Ni Gabhann J, Espinosa A, Wahren-Herlenius M, Jefferies CA: Self protection from anti-viral responses–Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-like receptors. PLoS One. 2010, 5: e11776.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Kong HJ, Anderson DE, Lee CH, Jang MK, Tamura T, Tailor P, Cho HK, Cheong J, Xiong H, Morse HC, Ozato K: Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol. 2007, 179: 26-30.View ArticlePubMedGoogle Scholar
  39. Zhang Z, Bao M, Lu N, Weng L, Yuan B, Liu YJ: The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat Immunol. 2013, 14: 172-178.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Shi M, Deng W, Bi E, Mao K, Ji Y, Lin G, Wu X, Tao Z, Li Z, Cai X, et al: TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol. 2008, 9: 369-377.View ArticlePubMedGoogle Scholar
  41. Zha J, Han KJ, Xu LG, He W, Zhou Q, Chen D, Zhai Z, Shu HB: The Ret finger protein inhibits signaling mediated by the noncanonical and canonical IkappaB kinase family members. J Immunol. 2006, 176: 1072-1080.View ArticlePubMedGoogle Scholar
  42. Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, Lascano J, Reinhard C, Santoni FA, Uchil PD, Chatel L, et al: TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011, 472: 361-365.PubMed CentralView ArticlePubMedGoogle Scholar
  43. Tareen SU, Emerman M: Human Trim5alpha has additional activities that are uncoupled from retroviral capsid recognition. Virology. 2011, 409: 113-120.PubMed CentralView ArticlePubMedGoogle Scholar
  44. Li Q, Yan J, Mao AP, Li C, Ran Y, Shu HB, Wang YY: Tripartite motif 8 (TRIM8) modulates TNFalpha- and IL-1beta-triggered NF-kappaB activation by targeting TAK1 for K63-linked polyubiquitination. Proc Natl Acad Sci USA. 2011, 108: 19341-19346.PubMed CentralView ArticlePubMedGoogle Scholar
  45. Poole E, Groves I, MacDonald A, Pang Y, Alcami A, Sinclair J: Identification of TRIM23 as a cofactor involved in the regulation of NF-kappaB by human cytomegalovirus. J Virol. 2009, 83: 3581-3590.PubMed CentralView ArticlePubMedGoogle Scholar
  46. Sjostrand M, Ambrosi A, Brauner S, Sullivan J, Malin S, Kuchroo VK, Espinosa A, Wahren-Herlenius M: Expression of the immune regulator tripartite-motif 21 is controlled by IFN regulatory factors. J Immunol. 2013, 191: 3753-3763.View ArticlePubMedGoogle Scholar
  47. Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin-Goguet F, Mothes W, Hazan U, Transy C, Pancino G, Nisole S: Human TRIM gene expression in response to interferons. PLoS One. 2009, 4: e4894.PubMed CentralView ArticlePubMedGoogle Scholar
  48. Rajsbaum R, Stoye JP, O'Garra A: Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells. Eur J Immunol. 2008, 38: 619-630.View ArticlePubMedGoogle Scholar
  49. Chelbi-Alix MK, Pelicano L, Quignon F, Koken MH, Venturini L, Stadler M, Pavlovic J, Degos L, de The H: Induction of the PML protein by interferons in normal and APL cells. Leukemia. 1995, 9: 2027-2033.PubMedGoogle Scholar
  50. Asaoka K, Ikeda K, Hishinuma T, Horie-Inoue K, Takeda S, Inoue S: A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem Biophys Res Commun. 2005, 338: 1950-1956.View ArticlePubMedGoogle Scholar
  51. Strandberg L, Ambrosi A, Espinosa A, Ottosson L, Eloranta ML, Zhou W, Elfving A, Greenfield E, Kuchroo VK, Wahren-Herlenius M: Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol. 2008, 28: 220-231.View ArticlePubMedGoogle Scholar
  52. Zhao W, Wang L, Zhang M, Yuan C, Gao C: E3 ubiquitin ligase tripartite motif 38 negatively regulates TLR-mediated immune responses by proteasomal degradation of TNF receptor-associated factor 6 in macrophages. J Immunol. 2012, 188: 2567-2574.View ArticlePubMedGoogle Scholar

Copyright

© Manocha et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement